These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15133780)

  • 41. On the second role of the random element in minimization.
    Kuznetsova OM
    Contemp Clin Trials; 2010 Nov; 31(6):587-8. PubMed ID: 20673852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparative evaluation of the balance behavior or various randomization methods for the unclassified case].
    Kundt G
    Stud Health Technol Inform; 2000; 77():190-4. PubMed ID: 11187540
    [No Abstract]   [Full Text] [Related]  

  • 43. Observational studies of drugs and mortality.
    Ray WA
    N Engl J Med; 2005 Dec; 353(22):2319-21. PubMed ID: 16319379
    [No Abstract]   [Full Text] [Related]  

  • 44. Determining causal exposure-response relationships with randomized concentration-controlled trials.
    Wang J
    J Biopharm Stat; 2014; 24(4):874-92. PubMed ID: 24697561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of malignant diseases: how shall new methods be tested?].
    Reizenstein P
    Lakartidningen; 1991 Sep; 88(36):2861. PubMed ID: 1895838
    [No Abstract]   [Full Text] [Related]  

  • 46. [Roaming through the methodology. XX. Randomization as a means of avoiding confounding through indication].
    Zielhuis GA
    Ned Tijdschr Geneeskd; 2000 Aug; 144(32):1528-31. PubMed ID: 10949635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Anticipations: risk of bias in cluster randomized trials].
    Vuoria P
    Duodecim; 2004; 120(3):357. PubMed ID: 15061017
    [No Abstract]   [Full Text] [Related]  

  • 48. Confounding by indication and past clinical trials.
    Porta M
    Epidemiology; 1997 Mar; 8(2):219-20. PubMed ID: 9229221
    [No Abstract]   [Full Text] [Related]  

  • 49. Use of Mendelian randomisation to assess potential benefit of clinical intervention.
    Burgess S; Butterworth A; Malarstig A; Thompson SG
    BMJ; 2012 Nov; 345():e7325. PubMed ID: 23131671
    [No Abstract]   [Full Text] [Related]  

  • 50. Diagnostics for Confounding of Time-varying and Other Joint Exposures.
    Jackson JW
    Epidemiology; 2016 Nov; 27(6):859-69. PubMed ID: 27479649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Active-comparator design and new-user design in observational studies.
    Yoshida K; Solomon DH; Kim SC
    Nat Rev Rheumatol; 2015 Jul; 11(7):437-41. PubMed ID: 25800216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Keeping patients safe while avoiding bias in randomised trials.
    Freemantle N; Van de Werf F
    BMJ; 2012 May; 344():e3297. PubMed ID: 22586233
    [No Abstract]   [Full Text] [Related]  

  • 53. Negative Control Outcomes: A Tool to Detect Bias in Randomized Trials.
    Arnold BF; Ercumen A
    JAMA; 2016 Dec; 316(24):2597-2598. PubMed ID: 28027378
    [No Abstract]   [Full Text] [Related]  

  • 54. Confounding due to changing background risk in adaptively randomized trials.
    Lipsky AM; Greenland S
    Clin Trials; 2011 Aug; 8(4):390-7. PubMed ID: 21610005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Workshop 3--source of bias in case series, patient cohorts, and randomised controlled trials.
    Yu IT; Tse SL
    Hong Kong Med J; 2011 Dec; 17(6):478-9. PubMed ID: 22147318
    [No Abstract]   [Full Text] [Related]  

  • 56. Confounding and bias in epidemiological investigations.
    Hammal DM; Bell CL
    Pediatr Hematol Oncol; 2002 Sep; 19(6):375-81. PubMed ID: 12186359
    [No Abstract]   [Full Text] [Related]  

  • 57. Recognizing chronological bias for what it is.
    Berger VW
    Clin Trials; 2011 Dec; 8(6):768; author reply 769. PubMed ID: 22167114
    [No Abstract]   [Full Text] [Related]  

  • 58. [Problems posed by cessation of controlled therapeutic trials before agreed duration].
    Sancho H; Flamant R
    Bull Cancer; 1974; 61(2):185-9. PubMed ID: 4619024
    [No Abstract]   [Full Text] [Related]  

  • 59. International aid projects come under the microscope.
    Gilbert N
    Nature; 2013 Jan; 493(7433):462-3. PubMed ID: 23344337
    [No Abstract]   [Full Text] [Related]  

  • 60. INTERMED: a tool for controlling for confounding variables and designing multimodal treatment.
    Huyse FJ; de Jonge P; Lyons JS; Stiefel FC; Slaets JP
    J Psychosom Res; 1999 Apr; 46(4):401-2. PubMed ID: 10340241
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.